Last reviewed · How we verify
Placebo 100 (for Aspirin 100)
Placebo 100 (for Aspirin 100) is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Control arm in clinical trials comparing Aspirin 100 mg efficacy. Also known as: Placebo100.
This is a placebo control formulation used in clinical trials to compare against Aspirin 100 mg.
This is a placebo control formulation used in clinical trials to compare against Aspirin 100 mg. Used for Control arm in clinical trials comparing Aspirin 100 mg efficacy.
At a glance
| Generic name | Placebo 100 (for Aspirin 100) |
|---|---|
| Also known as | Placebo100 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation contains no active pharmaceutical ingredient and serves as a control arm in Phase 3 clinical trials. It is designed to be indistinguishable from the active Aspirin 100 mg comparator to maintain blinding and assess the true efficacy of aspirin through comparison against inert treatment.
Approved indications
- Control arm in clinical trials comparing Aspirin 100 mg efficacy
Common side effects
Key clinical trials
- Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial (EARLY_PHASE1)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss (PHASE3)
- Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (PHASE4)
- Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (PHASE3)
- Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (PHASE4)
- Acetyl-leucine in Post-stroke Ataxia (PHASE3)
- Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo 100 (for Aspirin 100) CI brief — competitive landscape report
- Placebo 100 (for Aspirin 100) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Placebo 100 (for Aspirin 100)
What is Placebo 100 (for Aspirin 100)?
How does Placebo 100 (for Aspirin 100) work?
What is Placebo 100 (for Aspirin 100) used for?
Who makes Placebo 100 (for Aspirin 100)?
Is Placebo 100 (for Aspirin 100) also known as anything else?
What development phase is Placebo 100 (for Aspirin 100) in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in clinical trials comparing Aspirin 100 mg efficacy
- Also known as: Placebo100
- Compare: Placebo 100 (for Aspirin 100) vs similar drugs
- Pricing: Placebo 100 (for Aspirin 100) cost, discount & access